A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 487-498

  Chebli, Júlio Maria Fonseca ^a   Gaburri, Pedro Duarte ^a   Chebli, Liliana Andrade ^a   Ribeiro, Tarsila Campanha da Rocha ^a   Pinto, André Luiz Tavares ^a   Ambrogini Júnior, Orlando ^b   Cintra Damião, Adérson Omar Mourão ^c  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Agents; Biological; Inflammatory Bowel Disease; Ulcerative Colitis

Indexed keywords

ADALIMUMAB; BCG VACCINE; CERTOLIZUMAB PEGOL; DIPHTHERIA VACCINE; GOLIMUMAB; HAEMOPHILUS VACCINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INFLUENZA VACCINE; ISONIAZID; LAMIVUDINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MERCAPTOPURINE; MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RIBAVIRIN; TENOFOVIR; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COUGHING; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE SEVERITY; EPSTEIN BARR VIRUS INFECTION; GASTROENTERITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFLAMMATORY BOWEL DISEASE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LYMPHOMA; MELANOMA; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA AND VOMITING; NON MELANOMA SKIN CANCER; NUCLEAR MAGNETIC RESONANCE; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT SELECTION; RASH; REVIEW; RHEUMATOID ARTHRITIS; SMOKING CESSATION; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; UTERINE CERVIX DISEASE; VIRUS INFECTION; COMMUNICABLE DISEASE; COUNSELING; DRUG ANTAGONISM; PRACTICE GUIDELINE;

ANTIBODIES, MONOCLONAL; COMMUNICABLE DISEASES; COUNSELING; HUMANS; INFLAMMATORY BOWEL DISEASES; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897464866     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.890331     Document Type: Review

References (72)

1. Feagan BG, Panaccione R, Sandborn WJ et al: Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology, 2008; 135: 1493-99
2. de Souza GS, Vidigal FM, Chebli LA et al: Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn's disease patients. Med Sci Monit, 2013; 19: 716-22
3. Peyrin-Biroulet L, Oussalah A, Williet N et al: Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut, 2011; 60: 930-36
4. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology: Management of Crohn's disease in adults. Am J Gastroenterol, 2009; 104: 465-83
5. Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S: First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol, 2013; 10: 345-51
6. Vermeire S, Ferrante M, Rutgeerts P: Recent advances: personalised use of current Crohn's disease therapeutic options. Gut, 2013; 62: 1511-15
7. Bouguen G, Levesque BG, Feagan BG et al: Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. Clin Gastroenterol Hepatol, 2013; pii: S1542-3565(13)01301-3
8. Allen PB, Peyrin-Biroulet L: Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol, 2013; 29: 397-404
9. Louis E: Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease. Dig Dis, 2013; 31: 207-12
10. Halpin SJ, Ford AC: Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol, 2012; 107: 1474-82
11. Kane SV: Preparing for biologic or immunosuppressant therapy. Gastroenterol Hepatol, 2011; 7: 544-46
12. Nordgaard-Lassen I, Dahlerup JF, Belard E et al: Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J, 2012; 59: C4480
13. Dignass A, Lindsay JO, Sturm A et al: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis, 2012; 6: 991-1030
14. Buchner AM, Blonski W, Lichtenstein GR: Update on the management of Crohn's disease. Curr Gastroenterol Rep, 2011; 13: 465-74
15. Van Assche G, Lewis JD, Lichtenstein GR et al: The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol, 2011; 106: 1594-602
16. Ding T, Ledingham J, Luqmani R et al: Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee; BHPR. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology, 2010; 49: 2217-19
17. Bernheim O, Colombel JF, Ullman TA et al: The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut, 2013; 62: 1523-28
18. Beaugerie L: Use of immunosuppressants and biologicals in patients with previous cancer. Dig Dis, 2013; 31: 254-59
19. Siegel CA: Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut, 2012; 61: 459-65
20. Raaschou P, Simard JF, Holmqvist M, Askling J; ARTIS Study Group: Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ, 2013; 346: f1939
21. Siegel CA: Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther, 2011; 33: 23-32
22. Lewis JD, Gelfand JM, Troxel AB et al: Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol, 2008; 103: 1428-35
23. Kane S: Preparing the patient for immunosuppressive therapy. Curr Gastroenterol Rep, 2010; 12: 502-6
24. Wallis RS: Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis, 2009; 22: 403-9
25. Askling J, Fored CM, Brandt L et al: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum, 2005; 52: 1986-92
26. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V et al: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum, 2005; 52: 1766-72
27. Diel R, Loddenkemper R, Nienhaus A: Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest, 2010; 137: 952-68
28. Cotter J, Rosa B: The importance of IGRA in patients candidates for biological therapy. J Crohns Colitis, 2013; 7: 928-29
29. Duarte R, Campainha S, Cotter J et al: Portuguese Society of Pulmonology; Portuguese Society of Gastroenterology; Portuguese Society of Dermatology and Venereology; Portuguese Society of Rheumatology. Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy. Acta Reumatol Port, 2012; 37: 253-59
30. Theis VS, Rhodes JM: Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther, 2008; 27: 19-30
31. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement: Am J Respir Crit Care Med, 2000; 161(4 Pt 2): S221-47
32. Dusheiko G: Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int, 2013; 33: 137-50
33. Biancone L, Pavia M, Del Vecchio Blanco G et al: Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis, 2001; 7: 287-94
34. Loras C, Saro C, Gonzalez-Huix F et al: Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol, 2009; 104: 57-63
35. Lok A, McMahon BJ: Chronic hepatitis. Hepatology, 2007; 45: 507-39
36. Rahier JF, Ben-Horin S, Chowers Y et al: European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis, 2009; 3: 47-91
37. López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD: Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. World J Gastroenterol, 2013; 19: 1342-48
38. Gisbert JP, Chaparro M, Esteve M: Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 2011; 33: 619-33
39. Raimondo G, Allain JP, Brunetto MR et al: Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol, 2008; 49: 652-57
40. Shouval D, Shibolet O: Immunosuppression and HBV reactivation. Semin Liver Dis, 2013; 33: 167-77
41. Allen AM, Kim WR, Larson J, Loftus EV Jr: Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol, 2013;11: 1655-60
42. Brunasso AM, Puntoni M, Gulia A, Massone C: Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology, 2011; 50: 1700-11
43. Cepeda EJ, Williams FM, Ishimori ML et al: The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis, 2008; 67: 710-12
44. Walsh AJ, Weltman M, Burger D et al: Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. J Crohns Colitis, 2013; 7: e449-56
45. Melmed GY, Ippoliti AF, Papadakis KA et al: Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol, 2006; 101: 1834-40
46. Vermeire S, Van Assche G, Rutgeerts P: Vaccination and infection prevention in inflammatory bowel disease. FI000 Medicine Reports, 2010; 2: 80
47. Wasan SK, Baker SE, Skolnik PR, Farraye FA: A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol, 2010; 105: 1231-38
48. Carrera E, Manzano R, Garrido E: Efficacy of the vaccination in inflammatory bowel disease. World J Gastroenterol, 2013; 19: 1349-53
49. Gisbert JP, Chaparro M: Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol, 2013; 10: 277-85
50. Sands BE, Cuffari C, Katz J et al: Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis, 2004; 10: 677-92
51. Melmed GY: Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis, 2009;15: 1410-16
52. Sanchez-Tembleque MD, Corella C, Pérez-Calle JL: Vaccines and recommendations for their use in inflammatory bowel disease. World J Gastroenterol, 2013; 19: 1354-58
53. Shouval D: Hepatitis B vaccines. J Hepatol, 2003; 39(Suppl.1): S70-76
54. Rubin LG, Levin MJ, Ljungman P et al: 2013 IDSA Clinical Practice Guideline for vaccination of the immunocompromised host. Clin Infect Dis, 2014; 58(3): e44-100
55. Rahier JF, Ben-Horin S, Chowers Y et al: European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis, 2009; 3: 47-91
56. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC): Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2008; 57(RR-5): 1-30
57. Rahier JF: Prevention and management of infectious complications in IBD. Dig Dis, 2012; 30: 408-14
58. Ng SW, Mahadevan U: Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol, 2013; 9: 161-73
59. Cornish JA, Tan E, Teare J et al: A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut, 2007; 56: 830-37
60. Kornfeld D, Cnattingius S, Ekbom A: Pregnancy outcomes in women with inflammatory bowel disease-a population-based cohort study. Am J Obstet Gynecol, 1997; 177: 942-46
61. Gisbert JP, Chaparro M: Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol, 2013; 108: 1426-38
62. Bortlik M, Duricova D, Machkova N et al: Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children. Inflamm Bowel Dis, 2014 [Epub ahead of print]
63. Schnitzler F, Fidder H, Ferrante M et al: Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis, 2011; 17: 1846-54
64. Bortoli A, Pedersen N, Duricova D et al: Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther, 2011; 34: 724-34
65. Clark DA: Should anti-TNF-alpha therapy be offered to patients with infertility and recurrent spontaneous abortion? Am J Reprod Immunol, 2009; 61: 107-12
66. Mahadevan U: Fertility and pregnancy in the patient with inflammatory bowel disease. Gut, 2006; 55: 1198-206
67. Mañosa M, Navarro-Llavat M, Marín L et al: Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scand J Gastroenterol, 2013; 48: 427-32
68. Saougou I, Markatseli TE, Papagoras C et al: Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. Joint Bone Spine, 2013; 80: 34-37
69. Biedermann L, Rogler G, Vavricka SR et al: Pregnancy and breastfeeding in inflammatory bowel disease. Digestion, 2012; 86(Suppl.1): 45-54
70. Hyrich KL, Verstappen SM: Biologic therapies and pregnancy: the story so far. Rheumatology, 2013 [Epub ahead of print]
71. Mahadevan U, Martin CF, Sandler RS et al: PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology, 2012; 142(Suppl.1): S149
72. Mahadevan U, Wolf DC, Dubinsky M et al: Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol, 2013; 11: 286-92